STRATIFYER Molecular Pathology GmbH

Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data (2020) Kim WY, Rose T, Roghmann F, Eckstein M, Jarczyk J, Zengerling F, Sikic D, et al. Conference contribution Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Roghmann F, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Conference contribution Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, et al. Conference contribution Different Diagnostic Methods for Identification of FGFR Alteration in Advanced Urothelial Carcinomas: Proficiency Results Based on Multiple RNA Extraction Kits and Mutation Detection Methods (2020) Weyerer V, Stoehr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Immune Cell Gene Expression Signature is Associated with Improved Outcome in Muscle-Invasive Urothelial Bladder Cancer Patients Treated with Radical Cystectomy (2020) Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz RM, Pfannstiel C, Wullweber A, et al. Conference contribution Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Tumour immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes (2019) Eckstein M, Strissel P, Pfannstiel C, Chiappinelli K, Sikic D, Wach S, Taubert H, et al. Conference contribution The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes (2019) Pfannstiel C, Strissel P, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, et al. Journal article